thrombectomy
(4)
Vahid Saadat
Vahid Saadat is a serial medical device entrepreneur and co-founder and co-CEO of Inquis Medical, a Menlo Park, California company building the AVENTUS Thrombectomy System for treating venous thromboembolic disease and pulmonary embolism. With more than 25 years in medtech and over 200 issued and pending patents, he has founded or led a string of companies including Voyage Medical, USGI Medical, AngioTrax, Baxano and Arrinex (maker of ClariFix, later acquired by Stryker). He holds a BS in Electrical Engineering and an MS in Biomedical Engineering from the University of Texas at Austin, and runs Inquis alongside co-CEO Mojgan Saadat.
Eduardo Fonseca
Eduardo Fonseca is the CEO of XCath, a Houston- and Pangyo-based medtech company building endovascular robotic systems and steerable guidewires to treat stroke and other cerebrovascular conditions. A former Panamanian ambassador to the UAE and Saudi Arabia turned investor and operator, he joined the XCath board in 2019 and took the helm in 2023, also serving as interim CEO of sister company EndoQuest Robotics. Under his leadership XCath has logged a string of world firsts, including the first public remote mechanical thrombectomy demonstration and, in 2026, the world's first remote robotic intervention in a stroke patient.
Sungwoo Min
Sungwoo Min is the founder and CEO of Nventric, Inc., an Arcadia, California medical device company that designs, develops, and contract-manufactures vascular devices for the neurovascular, electrophysiology, and coronary markets. A Stanford-trained mechanical engineer who cut his teeth on R&D and marketing at Abbott Vascular and later led R&D programs at Johnson & Johnson, he started Nventric in 2019 to build the kind of life-saving catheters, stents, and thrombectomy systems he used to ship at the giants - this time end to end, ISO 13485 certified, with operations in the US and South Korea. He is a named inventor on multiple US patents for mechanical thrombectomy devices.
Adam Elsesser
Adam Elsesser is the co-founder, Chairman and CEO of Penumbra, the Alameda-based medical device company that pioneered aspiration thrombectomy for stroke. A former real estate lawyer turned operator, he has run Penumbra since 2004 and, in January 2026, agreed to sell it to Boston Scientific for roughly $14.5 billion.